Finance

Lists
Q3 2026 earnings • released • EPS beat +5,56% • Revenue beat +0,14%
See results
COLL:NASDAQ
Collegium Pharmaceutical Inc
24,21 USD
-3,78%
(-0,95) 1D
24,29 USD
+0,33% (+0,080)
After hours
Closed: 6-ноя., 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for COLL...
Open
24,06 USD
High
24,80 USD
Low
23,71 USD
Mkt. cap
788,17 млн
Avg. vol.
701,46 миң
Volume
775,58 миң
P/E ratio
19,72
52-wk high
50,79 USD
52-wk low
21,43 USD
EPS
1,23 USD
Beta
0,75
Shares outstanding
32,56 млн
No. of employees
423
Open
24,06 USD
High
24,80 USD
Low
23,71 USD
Mkt. cap
788,17 млн
Avg. vol.
701,46 миң
Volume
775,58 миң
P/E ratio
19,72
52-wk high
50,79 USD
52-wk low
21,43 USD
EPS
1,23 USD
Beta
0,75
Shares outstanding
32,56 млн
No. of employees
423
News stories
From web sources and news partners
About Collegium Pharmaceutical Inc
CEO-
Employees423
Founded2002
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitecollegiumpharma.com
Analyst ratings
Based on 6 analysts giving stock ratings to COLL in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for COLL in the last 3 months.
Highest
Current 24,21 USD
60,00 USD (+147,83%)
Average
46,67 USD (+92,77%)
Lowest
28,00 USD (+15,65%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alexander Xenakis
Truist Financial
Buy
Reiterated
49,00 USD
+102,4%
11/06/2026
David Amsellem
Piper Sandler
Hold
Reiterated
28,00 USD
+15,7%
11/06/2026
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
60,00 USD
+147,8%
11/06/2026
Jenna Davidner
Barclays
Buy
Maintained
48,00 USD
+98,3%
10/15/2026
Les Sulewski
Oppenheimer
Buy
Reiterated
50,00 USD
+106,5%
10/09/2026
Unknown Analyst
Oppenheimer
Buy
Initiated
50,00 USD
+106,5%
09/23/2026
Daniel Clark
Leerink Partners
Buy
Initiated
45,00 USD
+85,9%
09/09/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
49,00 USD
+102,4%
09/09/2026
Serge Belanger
Needham
Buy
Maintained
46,00 USD
+90%
08/06/2026
Unknown Analyst
Jefferies
Buy
Maintained
51,00 USD
+110,7%
03/20/2026
Last report
2026-ж., 5-ноя.
Fiscal period
Q3 2026
1,96 USD / 1,86 USD
+5,56%beat
Revenue / Est. (USD)
216,34 млн / 216,03 млн
+0,14%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
205,45 млн
193,52 млн
199,88 млн
216,34 млн
Cost of goods sold
21,60 млн
20,80 млн
21,22 млн
35,58 млн
Cost of revenue
21,60 млн
20,80 млн
21,22 млн
35,58 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
66,67 млн
86,35 млн
104,41 млн
99,59 млн
Operating expense
122,14 млн
141,82 млн
167,36 млн
154,94 млн
Total operating expenses
143,74 млн
162,62 млн
188,58 млн
190,51 млн
Operating income
61,71 млн
30,90 млн
11,30 млн
25,83 млн
Other non operating income
-
-
-
-
EBT including unusual items
29,04 млн
18,74 млн
-13,53 млн
7,91 млн
EBT excluding unusual items
45,98 млн
18,74 млн
-5,93 млн
5,01 млн
Income tax expense
12,07 млн
4,24 млн
1,52 млн
-13,85 млн
Effective tax rate
41,58%
22,65%
-11,23%
-175,22%
Other operating expenses
-
-
-
-
Net income
16,96 млн
14,50 млн
-15,05 млн
21,76 млн
Net profit margin
8,26%
7,49%
-7,53%
10,06%
Earnings per share
2,04
1,76
1,92
1,96
Interest and investment income
3,56 млн
3,71 млн
2,29 млн
1,13 млн
Interest expense
-19,29 млн
-15,86 млн
-19,52 млн
-21,94 млн
Net interest expenses
-15,73 млн
-12,16 млн
-17,23 млн
-20,82 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
118,11 млн
86,83 млн
76,06 млн
81,66 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору